Freire Teresa, Berois Nora, Sóñora Cecilia, Varangot Mario, Barrios Enrique, Osinaga Eduardo
Laboratorio de Oncología Básica y Biología Molecular, Dpto. de Bioquímica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Int J Cancer. 2006 Sep 15;119(6):1383-8. doi: 10.1002/ijc.21959.
The evaluation of disseminated epithelial tumor cells in patients with early stages of breast cancer has generated considerable interest because of its potential association with poor clinical outcome. Considering that O-glycosylation pathways are frequently altered in breast cancer, we performed this work to evaluate the potential usefulness of UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts) (a family of glycosyltransferases which catalyze the first key step of mucin-type O-glycosylation) to detect disseminated cells in bone marrow samples from patients with operable breast cancer. Using RT-PCR assays, we studied the gene expression of 9 enzymes (ppGalNAc-T1-T9). Among the ppGalNAc-Ts expressed by breast tumors (-T1, -T2, -T3, -T6 and -T7), the best specificity (negative results on all PBMN cell samples from healthy donors) was shown for ppGalNAc-T6. Thus, we selected this enzyme as a target gene for further evaluation. ppGalNAc-T6 mRNA was found in 22/25 (88%) breast cancer samples, in all 3 human breast cancer cell lines evaluated (MCF-7, ZR75-1 and T47D), in 1/30 (3%) PBMN cells and 0/19 bone marrow samples obtained from patients without cancer. Using this method, 22/61 (36%) patients with breast cancer, who underwent curative surgery, showed positive ppGalNAc-T6 mRNA in bone marrow aspirates obtained prior to surgery, including 11/34 patients with stage-I or -II, without histopathological lymph node involvement. In a preliminary follow-up evaluation, 19/61 patients experienced recurrence of the disease. ppGalNAc-T6 was positive in 11/19 (57.9%) of these patients. Interestingly, in the group of patients without lymph node involvement, disease recurrence was observed in 54.5% of patients who showed ppGalNAc-T6 mRNA-positive bone marrow aspirates and only in 4.3% of patients when ppGalNAc-T6 was negative (p = 0.014). These results indicate that ppGalNAc-T6 mRNA could be a specific marker applicable to the molecular diagnosis of breast cancer cells dissemination.
由于其与不良临床结局的潜在关联,对早期乳腺癌患者中播散性上皮肿瘤细胞的评估引起了广泛关注。鉴于O-糖基化途径在乳腺癌中经常发生改变,我们开展了这项工作,以评估UDP-N-乙酰-D-半乳糖胺:多肽N-乙酰半乳糖胺基转移酶(ppGalNAc-Ts,一类催化粘蛋白型O-糖基化第一步关键反应的糖基转移酶家族)在检测可手术乳腺癌患者骨髓样本中播散细胞方面的潜在效用。我们使用逆转录聚合酶链反应(RT-PCR)分析方法,研究了9种酶(ppGalNAc-T1-T9)的基因表达。在乳腺癌表达的ppGalNAc-Ts中(-T1、-T2、-T3、-T6和-T7),ppGalNAc-T6表现出最佳的特异性(在所有健康供体的外周血单核细胞样本中均为阴性结果)。因此,我们选择该酶作为进一步评估的靶基因。在25份乳腺癌样本中的22份(88%)、所有评估的3种人乳腺癌细胞系(MCF-7、ZR75-1和T47D)、30份外周血单核细胞样本中的1份(3%)以及19份来自无癌患者的骨髓样本中的0份中发现了ppGalNAc-T6 mRNA。使用该方法,61例接受根治性手术的乳腺癌患者中有22例(36%)在术前获得的骨髓抽吸物中显示ppGalNAc-T6 mRNA阳性,其中包括34例I期或II期、无组织病理学淋巴结受累的患者中的11例。在初步的随访评估中,61例患者中有19例疾病复发。这些复发患者中有11例(57.9%)的ppGalNAc-T6呈阳性。有趣地是,在无淋巴结受累的患者组中,ppGalNAc-T6 mRNA阳性骨髓抽吸物的患者中有54.5%出现疾病复发,而ppGalNAc-T6阴性的患者中只有4.3%复发(p = 0.014)。这些结果表明,ppGalNAc-T6 mRNA可能是一种适用于乳腺癌细胞播散分子诊断的特异性标志物。